We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
CI's Unit Unveils Offering to Expand Access to GLP-1 Medications
Read MoreHide Full Article
The health services arm of The Cigna Group (CI - Free Report) , Evernorth, recently introduced a pharmacy benefit offering designed to enhance access to the weight loss medications WEGOVY and ZEPBOUND. This innovative offering addresses critical market demand by providing affordable access to weight loss medications for both patients and health plan sponsors.
For patients, the monthly copay for GLP-1 weight loss medications will be capped at $200 or less, offering a more affordable option than cash payment programs. Additionally, these copayments will contribute toward the patient’s annual deductible. This arrangement can result in annual savings of up to $3,600 when compared with purchasing the medications directly or through alternative consumer programs.
Furthermore, patients will gain access to FDA-approved treatments coupled with safety protocols from Express Scripts, which are designed to minimize the risk of harmful drug interactions. The process of prior authorization has also been streamlined and automated to ensure faster access to these medications. Patients have the added flexibility of choosing from a wide network of local retail pharmacies or opting for home delivery via Evernorth’s EnGuide Pharmacy, which is supported by clinicians who specialize in GLP-1 medications and offer enhanced care.
Employers and other health plan sponsors stand to gain substantial advantages from this new offering. One key benefit is the notable decrease in the overall net cost per prescription for GLP-1 medications, resulting in meaningful cost savings. Additionally, health plan sponsors will be able to provide patients with access to the most suitable medication for their individual needs, maintaining both clinical safety and cost-effectiveness without sacrificing choice or quality of care.
Benefits of the Recent Move to Cigna
The ulterior motive of Evernorth remains to bring meaningful cost savings and improved health outcomes for its existing clients using the GLP-1 solution suite. The new pharmacy benefit offering is expected to upgrade the comprehensive suite of GLP-1 solutions. Apart from the recent addition, the solutions suite also includes EncircleRx, a cost-saving financial model that currently covers more than 9 million lives and has delivered $200 million in savings to health plans since 2024. It also features a personalized clinical support program, EnReachRx, designed to provide enhanced assistance in dispensing GLP-1 prescription medications.
The lucrativeness of the new pharmacy benefit offering is likely to retain existing customers and attract new ones toward opting for the GLP-1 solutions. Increased utilization of the solutions is expected to bring higher revenues to the Evernorth segment. This, in turn, will bode well for its parent company, Cigna. The unit accounts for a significant portion of CI’s revenues. In the first quarter of 2025, Evernorth contributed 82% to the overall adjusted revenues of Cigna.
CI’s Share Price Performance & Zacks Rank
Shares of Cigna have gained 13.3% year to date against the industry’s 30% decline. CI currently carries a Zacks Rank #2 (Buy).
CorMedix’s earnings surpassed estimates in each of the last four quarters, the average surprise being 25.82%. The Zacks Consensus Estimate for CRMD’s 2025 earnings is pegged at 93 cents per share. A loss of 30 cents was reported in the prior year. The same for revenues implies an increase of nearly four-fold from the year-ago actual. The consensus mark for CRMD’s 2025 earnings has moved 29.2% north in the past 30 days.
Encompass Health’s earnings beat estimates in each of the trailing four quarters, the average surprise being 12.33%. The Zacks Consensus Estimate for EHC’s 2025 earnings indicates a rise of 13.1%, while the same for revenues implies an improvement of 9.5% from the respective year-ago actuals. The consensus mark for EHC’s 2025 earnings has moved 4.6% north in the past 30 days.
The bottom line of Integer outpaced estimates in three of the trailing four quarters and missed the mark once, the average surprise being 2.77%. The Zacks Consensus Estimate for ITGR’s 2025 earnings indicates a rise of 19.4%, while the same for revenues implies an improvement of 7.7% from the respective year-ago actuals. The consensus mark for ITGR’s 2025 earnings has moved 4.5% north in the past 30 days.
Shares of CorMedix and Encompass Health have gained 52.4% and 28.5%, respectively, year to date. However, Integer stock has declined 11.1% in the same time frame.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
CI's Unit Unveils Offering to Expand Access to GLP-1 Medications
The health services arm of The Cigna Group (CI - Free Report) , Evernorth, recently introduced a pharmacy benefit offering designed to enhance access to the weight loss medications WEGOVY and ZEPBOUND. This innovative offering addresses critical market demand by providing affordable access to weight loss medications for both patients and health plan sponsors.
For patients, the monthly copay for GLP-1 weight loss medications will be capped at $200 or less, offering a more affordable option than cash payment programs. Additionally, these copayments will contribute toward the patient’s annual deductible. This arrangement can result in annual savings of up to $3,600 when compared with purchasing the medications directly or through alternative consumer programs.
Furthermore, patients will gain access to FDA-approved treatments coupled with safety protocols from Express Scripts, which are designed to minimize the risk of harmful drug interactions. The process of prior authorization has also been streamlined and automated to ensure faster access to these medications. Patients have the added flexibility of choosing from a wide network of local retail pharmacies or opting for home delivery via Evernorth’s EnGuide Pharmacy, which is supported by clinicians who specialize in GLP-1 medications and offer enhanced care.
Employers and other health plan sponsors stand to gain substantial advantages from this new offering. One key benefit is the notable decrease in the overall net cost per prescription for GLP-1 medications, resulting in meaningful cost savings. Additionally, health plan sponsors will be able to provide patients with access to the most suitable medication for their individual needs, maintaining both clinical safety and cost-effectiveness without sacrificing choice or quality of care.
Benefits of the Recent Move to Cigna
The ulterior motive of Evernorth remains to bring meaningful cost savings and improved health outcomes for its existing clients using the GLP-1 solution suite. The new pharmacy benefit offering is expected to upgrade the comprehensive suite of GLP-1 solutions. Apart from the recent addition, the solutions suite also includes EncircleRx, a cost-saving financial model that currently covers more than 9 million lives and has delivered $200 million in savings to health plans since 2024. It also features a personalized clinical support program, EnReachRx, designed to provide enhanced assistance in dispensing GLP-1 prescription medications.
The lucrativeness of the new pharmacy benefit offering is likely to retain existing customers and attract new ones toward opting for the GLP-1 solutions. Increased utilization of the solutions is expected to bring higher revenues to the Evernorth segment. This, in turn, will bode well for its parent company, Cigna. The unit accounts for a significant portion of CI’s revenues. In the first quarter of 2025, Evernorth contributed 82% to the overall adjusted revenues of Cigna.
CI’s Share Price Performance & Zacks Rank
Shares of Cigna have gained 13.3% year to date against the industry’s 30% decline. CI currently carries a Zacks Rank #2 (Buy).
Image Source: Zacks Investment Research
Other Stocks to Consider
Some other top-ranked stocks in the Medical space are CorMedix Inc. (CRMD - Free Report) , Encompass Health Corporation (EHC - Free Report) and Integer Holdings Corporation (ITGR - Free Report) , each currently sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
CorMedix’s earnings surpassed estimates in each of the last four quarters, the average surprise being 25.82%. The Zacks Consensus Estimate for CRMD’s 2025 earnings is pegged at 93 cents per share. A loss of 30 cents was reported in the prior year. The same for revenues implies an increase of nearly four-fold from the year-ago actual. The consensus mark for CRMD’s 2025 earnings has moved 29.2% north in the past 30 days.
Encompass Health’s earnings beat estimates in each of the trailing four quarters, the average surprise being 12.33%. The Zacks Consensus Estimate for EHC’s 2025 earnings indicates a rise of 13.1%, while the same for revenues implies an improvement of 9.5% from the respective year-ago actuals. The consensus mark for EHC’s 2025 earnings has moved 4.6% north in the past 30 days.
The bottom line of Integer outpaced estimates in three of the trailing four quarters and missed the mark once, the average surprise being 2.77%. The Zacks Consensus Estimate for ITGR’s 2025 earnings indicates a rise of 19.4%, while the same for revenues implies an improvement of 7.7% from the respective year-ago actuals. The consensus mark for ITGR’s 2025 earnings has moved 4.5% north in the past 30 days.
Shares of CorMedix and Encompass Health have gained 52.4% and 28.5%, respectively, year to date. However, Integer stock has declined 11.1% in the same time frame.